InspireMD (NYSE:NSPR) Coverage Initiated at StockNews.com

Equities research analysts at StockNews.com assumed coverage on shares of InspireMD (NYSE:NSPR) in a note issued to investors on Wednesday. The firm set a “sell” rating on the stock.

Separately, Lake Street Capital assumed coverage on shares of InspireMD in a research note on Wednesday, December 11th. They issued a “buy” rating and a $5.00 price objective for the company.

InspireMD Stock Up 5.8 %

NYSE NSPR opened at $2.57 on Wednesday. The stock’s 50-day simple moving average is $2.83 and its two-hundred day simple moving average is $2.73. InspireMD has a twelve month low of $1.81 and a twelve month high of $3.42. The company has a market capitalization of $67.03 million, a price-to-earnings ratio of -3.43 and a beta of 0.99.

InspireMD (NYSE:NSPR) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.16) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.04. The company had revenue of $1.81 million for the quarter, compared to analysts’ expectations of $1.74 million. InspireMD had a negative return on equity of 69.42% and a negative net margin of 413.96%. During the same period last year, the firm posted ($0.15) EPS. On average, equities analysts expect that InspireMD will post -0.79 earnings per share for the current fiscal year.

Hedge Funds Weigh In On InspireMD

Institutional investors and hedge funds have recently bought and sold shares of the stock. Legato Capital Management LLC purchased a new position in shares of InspireMD in the fourth quarter valued at about $47,000. Parkman Healthcare Partners LLC bought a new stake in shares of InspireMD in the third quarter worth about $279,000. Finally, Affiance Financial LLC bought a new stake in shares of InspireMD in the third quarter worth about $492,000. 44.78% of the stock is currently owned by institutional investors.

InspireMD Company Profile

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.